- Home
- MFH vs DRUG Comparison
MFH vs DRUG Comparison
Compare MFH & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- DRUG
- Stock Information
- Founded
- MFH 2011
- DRUG 2019
- Country
- MFH United States
- DRUG United States
- Employees
- MFH N/A
- DRUG N/A
- Industry
- MFH Finance: Consumer Services
- DRUG Pharmaceuticals and Biotechnology
- Sector
- MFH Finance
- DRUG Health Care
- Exchange
- MFH Nasdaq
- DRUG Nasdaq
- Market Cap
- MFH 271.3M
- DRUG 233.2M
- IPO Year
- MFH N/A
- DRUG N/A
- Fundamental
- Price
- MFH $3.07
- DRUG $25.95
- Analyst Decision
- MFH
- DRUG Strong Buy
- Analyst Count
- MFH 0
- DRUG 6
- Target Price
- MFH N/A
- DRUG $83.25
- AVG Volume (30 Days)
- MFH 145.7K
- DRUG 29.2K
- Earning Date
- MFH 06-10-2025
- DRUG 05-15-2025
- Dividend Yield
- MFH N/A
- DRUG N/A
- EPS Growth
- MFH N/A
- DRUG N/A
- EPS
- MFH N/A
- DRUG N/A
- Revenue
- MFH N/A
- DRUG N/A
- Revenue This Year
- MFH N/A
- DRUG N/A
- Revenue Next Year
- MFH N/A
- DRUG N/A
- P/E Ratio
- MFH N/A
- DRUG N/A
- Revenue Growth
- MFH 125.92
- DRUG N/A
- 52 Week Low
- MFH $1.03
- DRUG $0.93
- 52 Week High
- MFH $8.86
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- MFH 24.86
- DRUG 30.05
- Support Level
- MFH $3.06
- DRUG $26.30
- Resistance Level
- MFH $5.79
- DRUG $31.20
- Average True Range (ATR)
- MFH 0.62
- DRUG 2.50
- MACD
- MFH -0.30
- DRUG -0.55
- Stochastic Oscillator
- MFH 2.96
- DRUG 5.59
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.